A week after acknowledging the failure of its lead candidate in a Phase III trial, Vical has ended development of the DNA vaccine candidate and eliminated more than half its staff.
Vical has shrunk its workforce from 74 to 34 staffers in a...
Vical has been hit with trial flop after trial flop, from cancer vaccines and herpes vaccines to just last week a cytomegalovirus vaccine licensed from Astellas. Now, the micro-cap biotech is letting go of around half of its workforce.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Vical (VICL):